Novo Holdings A/S / Catalent (manufacturing sites)
2024 · Acquisition/Merger · $11.0B · Complete
Announcement Sentiment
57
Neutral / mixed
Outcome Score
81
Worked — the deal delivered on its rationale.
Novo Holdings acquired Catalent in an all-cash deal with a total enterprise value of approximately $16.5 billion ($63.50/share), closed December 18, 2024 after EU Commission unconditional approval (Dec 6, 2024) and the FTC declining to challenge. Concurrently, Novo Nordisk acquired three Catalent fill-finish sites (Anagni, Italy; Bloomington, Indiana; Brussels, Belgium) from Novo Holdings for $11 billion to secure and scale GLP-1 fill-finish capacity for Wegovy and Ozempic, expanding Novo Nordisk's fill-finish footprint from 11 to 14 sites.